New research, "Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor-Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial." #BreastCancer #Oncology #OncTwitter @StLukesHealthMD https://t.co/LmuK
Phase 3 Study Evaluation: Serum Thymidine Kinase 1 in SWOG S0226 Breast Cancers. https://t.co/ERiHOsGJOl https://t.co/6Ml1Iu6TVS
RT @ProfAMThompson: New article, "Evaluating Serum Thymidine Kinase 1 in Hormone Receptor-Positive Metastatic #BreastCancer Patients Receiv…
RT @ProfAMThompson: New article, "Evaluating Serum Thymidine Kinase 1 in Hormone Receptor-Positive Metastatic #BreastCancer Patients Receiv…
RT @ProfAMThompson: New article, "Evaluating Serum Thymidine Kinase 1 in Hormone Receptor-Positive Metastatic #BreastCancer Patients Receiv…
New article, "Evaluating Serum Thymidine Kinase 1 in Hormone Receptor-Positive Metastatic #BreastCancer Patients Receiving First-Line Endocrine Therapy in the SWOG S0226 Trial" in the @CCR_AACR Journal. #OncTwitter @StLukesHealthMD https://t.co/r8ODyxe3
Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor-Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial https://t.co/C2jjm5hbo6
Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor–Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial https://t.co/1MABD0mA1x
Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor–Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial https://t.co/mXqOsFd9DL
Tamoxifen vanligt att ge till bröstcancerpatienter i tidigt skede. Har ni som räknar med höga TAM för viccen tagit hänsyn till detta? SWOG-studien indikerar att Divitum är värdelös för patienter som redan fått Tamoxifen (se sup fig 2b i referens). https:/
RT @YaleCancer: New research in @CCR_AACR by Dr. Lajos Pusztai & @SWOG colleagues shows a serum test may identify patients with advanced ho…
RT @YaleCancer: New research in @CCR_AACR by Dr. Lajos Pusztai & @SWOG colleagues shows a serum test may identify patients with advanced ho…
RT @YaleCancer: New research in @CCR_AACR by Dr. Lajos Pusztai & @SWOG colleagues shows a serum test may identify patients with advanced ho…
New research in @CCR_AACR by Dr. Lajos Pusztai & @SWOG colleagues shows a serum test may identify patients with advanced hormone receptor-positive #breastcancer with excellent long term outcome with single drug therapy. @SmilowCancer @YaleMed @YNHH #bc
(3/3) Biovica: Länk till studien som publicerats i den högt rankade vetenskapliga tidskriften Clinical Cancer Research som ges ut av American Association for Cancer Research (AACR) 👇🏻 https://t.co/9228ueh8l9
Can disease in pts w low sTK1 activity levels be treated initially w endocrine tx only? #bcsm Evaluating Serum Thymidine Kinase 1 in Hormone Receptor Positive Metastatic Breast Cancer Patients Receiving First Line Endocrine Therapy in the SWOG S0226 Trial
Evaluating Serum Thymidine Kinase 1 in Hormone Receptor Positive Metastatic Breast Cancer Patients Receiving First Line Endocrine Therapy in the SWOG S0226 Trial https://t.co/26zI28rahI